Efficacy and Safety of IVIG-L in ITP Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

October 31, 2001

Study Completion Date

March 31, 2002

Conditions
Purpura, Thrombocytopenic, Idiopathic
Interventions
DRUG

IVIG-L

Trial Locations (6)

15-276

Hematology Clinic, Medical University of Bialystok, Bialystok

80-952

Haematology Clinic, Medical University of Gdansk, Gdansk

93-509

Clinic of Haematology, Medical University of Lodz, Lodz

00-909

Clinical of Internal Diseases and haematology with Bone marrow Transplantation Unit, Central Academic Hospital, Medical Military Academy, Warsaw

00-957

Institute of Haematology and Transfusiology, Warsaw

02-097

Haematology Clinic, Medical University of Warsaw, Warsaw

Sponsors
All Listed Sponsors
lead

Prothya Biosolutions

INDUSTRY

NCT00151840 - Efficacy and Safety of IVIG-L in ITP Patients | Biotech Hunter | Biotech Hunter